bioRxiv Science⌕ Search

Biology subjects

Jeon, H.

Publications and source records attributed to Jeon, H..

At least 19 recordsLinked to original sources

Beyond the attractor: closed-loop stimulation design for learning multistable neural dynamics

Online identification of nonlinear dynamical systems faces two challenges. Noisy, partial observations make the latent state difficult to estimate. Local attractors can also keep passive trajectories in regions that reveal little about the unknown dynamics. Both challenges commonly arise in closed-loop neural experiments where stimulation must be chosen from noisy spike counts, while neural activity may remain near a stable state unless stimulation drives it elsewhere. We address this problem by actively selecting inputs to collect informative observations during the experiment. We introduce PALDI (Planning-based Active Latent Dynamics Identification), which combines extended-Kalman state prediction, single-step Laplace state updates, blockwise Gaussian parameter updates, and finite-horizon planning. Its parameter expected-information-gain surrogate combines dynamics sensitivity with state Fisher information and discounts apparent parameter information when latent states are uncertain. We compare PALDI with nonadaptive inputs, a myopic policy, and two active baselines: the one-step D-optimal method FLEX and receding-horizon curiosity with uncertainty sampling. On a bistable Wilson-Cowan model of excitatory and inhibitory populations, PALDI approaches the true-model reference and remains strongest as the observation signal-to-noise ratio decreases or the readout geometry becomes biased. We then test identification in a spiking decision network where we use a reduced dynamics and observation model to approximate the data-generating process. PALDI reaches a median held-out prediction R2 of 0.90, close to a fitted reference, and its model gives the highest change-of-mind success among identification policies. Information-guided finite-horizon planning is a practical strategy for identifying neural circuit dynamics with closed-loop stimulation.

neuroscience↗

Circular Data Analysis for Spatial Omics

Many biological quantities in omics are inherently periodic or directional, including circadian phase, cell-cycle position, and cellular orientation. Treating such quantities as ordinary linear variables can introduce artificial discontinuities and obscure biological interpretation. Circular methods are well developed across directional statistics, bioinformatics, and spatial statistics, but practical guidance for omics applications remains limited. We present key considerations for circular data analysis in single-cell and spatial omics, including the provenance and observational unit of the circular quantity, the inferential or predictive objective, the distinction between tissue composition and residual spatial dependence, and the choice of appropriate models. We describe relevant approaches for circular representation, inference, clustering, regression, machine learning, and spatial analysis, together with representative R software. Their practical use is illustrated through spatial transcriptomic case studies of derived circadian peak phase in a mouse model of Alzheimer's disease and latent cell-cycle position in human ovarian cancer. These examples demonstrate how the definition of the angle, its observational unit, and tissue heterogeneity shape appropriate analysis and interpretation, including when spatial modeling is not warranted. We conclude with practical recommendations and directions for future methodological development.

bioinformatics↗

Cryo-EM structure and biochemical characterization of a BRAF/CRAF heterodimer: Negative charge in the NtA motif is not required for RAF activation

Upon RAS-driven membrane recruitment, RAF kinases ARAF, BRAF and CRAF are activated via formation of homo- or hetero-dimers to initiate signaling through the MAP kinase cascade. Although RAF heterodimers are important for both physiologic and oncogenic signaling, they have been little studied at a structural and biochemical level. Here we report the preparation, biochemical characterization, and the cryo-EM structure of a 14-3-3-bound BRAF/CRAF heterodimer complex. The heterodimer exhibited kinetic parameters and sensitivity to a panel of twelve structurally diverse RAF inhibitors that were closely similar to, or intermediate between, those of BRAF and CRAF homodimers. Cryo-EM structures of the heterodimer with and without MEK1 revealed an overall organization essentially identical to that of RAF homodimers, but with an asymmetric interaction in the MEK1-bound structure in which the BRAF N-terminal acidic (NtA) motif extends across the dimer interface to engage the CRAF RKTR motif. Mutagenesis of this interface unexpectedly revealed that replacing the acidic NtA sequence with a basic RARA sequence yields highly active RAF homodimers and heterodimers, demonstrating that negative charge in the NtA motif is not required for activity. Collectively, our findings suggest that the charge state of the NtA motif influences RAF activity through effects on local backbone dynamics and the stability of the inactive kinase conformation, rather than via stereospecific recognition across the dimer interface.

biophysics↗

High-variance phenome database reveals important roles of WD40 proteins in the plant pathogenic fungus Fusarium graminearum

WD40 is a highly conserved protein domain in eukaryotes, playing a critical role in various cellular process. We conducted genome-wide functional analysis of WD40 genes in Fusarium graminearum-a phytopathogenic fungus that causes severe yield loss and mycotoxin contamination in major cereal crops. Comprehensive phenome analysis of 119 WD40 gene deletion mutants across 22 distinct phenotypic traits revealed phenotypic divergence within the phenome, establishing a strong correlation between virulence and sexual reproduction. Notably, 21 core WD40 genes were identified, offering valuable insights into divergent biological processes. Pilot interactome studies of Fgwd101 and Fgwd133 provided further insights into their potential pathobiological functions. Our investigation contributes to broadening our knowledge of the biological mechanisms underlying fungal pathogenesis and may assist in the identification of targets for antifungal agents.

molecular biology↗

Music-Inspired Acoustic-Piezoelectric Stimulation Accelerates Extracellular Vesicle Production and Programs Therapeutic Function

Macrophage small extracellular vesicles (sEVs) carry phenotype-linked cargo and bioactivity for immunomodulation and regeneration, but therapeutic translation is limited by low secretion and poor control of function. We introduce a music-activated piezoelectric nanofiber substrate (PES) that converted audible sound into programmable electrical stimulation to enhance sEV biogenesis while tuning macrophage polarization. Adjusting acoustic parameters increased sEV yield, while musically inspired "assemblies" biased macrophage phenotypes: dissonant, low-frequency stimuli promoted M1-like inflammation, whereas consonant, higher-frequency stimuli favored M2-like, regenerative states. These shifts produced distinct sEV cargo and bioactivities. We rationally designed customized music stimulus that maximized both vesicle production and M2 bias, yielding sEVs exhibited regeneration potentials. This work establishes a programmable acoustic-piezoelectric strategy to scale macrophage sEV production while tailoring their therapeutic potency.

bioengineering↗

Real world data based evaluation of a novel target-mediated drug disposition approximation model

Target-mediated drug disposition (TMDD) models have been widely used to describe nonlinear pharmacokinetic profiles driven by high-affinity, low-capacity drug-target binding. A pTMDD model, derived by applying the Pade approximation of the quasi-steady-state (QSS) model (qTMDD) was previously proposed. Although pTMDD model showed a comparable estimation accuracy while maintaining computational efficiency, further validation in realistic clinical scenarios and comprehensive performance evaluations have been needed to assess its practical applicability. Here, we evaluated the pTMDD model using five clinical datasets and extended the previous study that focused on simulations. Using the full TMDD as a reference, the approximation models were compared in terms of the parameter estimation results (parameter estimates, relative standard error values and model diagnostics) and computational efficiency (estimation and bootstrap runtimes). The pTMDD model, previously validated in simulation settings, also preserved the estimation accuracy while reducing the computation time of the clinical data. Both pTMDD and qTMDD remained close to the full TMDD model, whereas Michaelis-Menten TMDD (mTMDD) model showed substantial discrepancies especially at low doses, including biased estimates for key TMDD-related parameters (e.g., kdeg, kint, krec, and kup) and higher objective function values. Moreover, pTMDD was faster than qTMDD in four of the five cases compared to the full TMDD. The time savings were particularly pronounced for larger datasets, supporting the computational efficiency of pTMDD. Q2PCONV, an R Shiny application that converts NONMEM code from qTMDD to pTMDD, was also developed, thereby making this new approximation more accessible to researchers. The findings support pTMDD as a practical alternative to existing TMDD approximation models. Author SummaryTarget-mediated drug disposition (TMDD) models describe a high-affinity, low-capacity binding between drug and its target. To avoid overparameterization, approximation models have been used. The two primary models are Michaelis-Menten model (mTMDD), which is accurate only at high doses, and Quasi-steady-state (qTMDD), which is accurate in wider ranges but requires longer runtime. We have proposed a new approximation model named pTMDD. Here, we evaluated pTMDD using five real clinical trial datasets to assess its practical usefulness. pTMDD produced parameter estimates closer to those from the full TMDD model and showed lower uncertainty than both the full TMDD and mTMDD models. In terms of computational efficiency, pTMDD reduced estimation time by an average of 11% and bootstrap time by an average of 6% relative to qTMDD across cases. In addition, we also developed an R shiny application to help researchers apply pTMDD in practice. Our work supports pTMDD as a practical and efficient tool for TMDD modeling in drug development.

pharmacology and toxicology↗

Exact formula of the total quasi-steady state approximation in competitive target-mediated drug disposition

Competitive target-mediated drug disposition (competitive TMDD) arises when two drugs compete for the same target receptor. These dynamics can be characterized by the full competitive TMDD model; yet, its complexity motivated the use of a reduced model, which is invalid under high receptor concentrations. While this problem can be resolved by using the total quasi-steady state approximation (tQSSA), which remains valid for all receptor conditions, the exact formula of the tQSSA-based reduced model--competitive qTMDD--has remained unknown for 15 years, as it requires solving a cubic equation and the nontrivial task of identifying a biologically meaningful solution. Consequently, researchers have relied on numerical approximation methods, which impose substantial computational costs to maintain accuracy and thereby hinder their practical use in complex real-world applications. To address this problem, we derive--for the first time--a real-valued exact formula for competitive qTMDD by leveraging analytic properties of cubic equations and geometric characteristics of their roots in the complex plane. This exact formula improved computational speed by more than 11-fold compared to previous numerical approximation methods, thereby enabling Bayesian inference using competitive qTMDD, which had been impractical due to excessive computational time. When applied to real-world data from clinical trials, competitive qTMDD estimated pharmacological parameter estimates comparable to those from the full competitive TMDD model while requiring only 30-43% of the computation time. Importantly, this estimation using competitive qTMDD remained consistently accurate regardless of data sparsity, whereas the previous reduced model produced biased estimates under sparse sampling conditions. By ensuring precise biological interpretation of drug systems even in complex real-world scenarios, the exact formula of competitive qTMDD has the potential to significantly streamline the drug development and clinical testing process. Our exact formula also consists entirely of real-valued terms, allowing seamless integration into existing pharmacometrics software. Author SummaryCompetitive target-mediated drug disposition (competitive TMDD) occurs when two drugs compete for the same target receptor. Analyzing this interaction has faced a dilemma for 15 years: choosing between a full model that is accurate but computationally intensive, and a reduced model that is fast but often loses accuracy under real-world clinical conditions. Researchers tried to solve this dilemma by deriving an accurate reduced model; however, it was mathematically challenging. As a result, they had to rely on numerical approximations--which require substantial computational power to maintain the accuracy needed for clinical use, making them impractical in real-world scenarios. In this study, we derive a first-ever exact formula for the new reduced model that is accurate across all biological conditions. This formula computes more than 11 times faster than previous numerical methods, making advanced statistical analyses--such as Bayesian inference--feasible for the first time in this context. When applied to real-world clinical data for Anakinra and rhIL-7-hyFc, our method yielded parameter estimates as accurate as the full model but required significantly less computation time. This breakthrough provides a more accurate biological interpretation and better guidance for determining the right drug dose, potentially accelerating drug development and reducing associated costs.

pharmacology and toxicology↗

Automated, modular assembly of reconstituted cell-free systems from in vitro-produced components

High-performance cell-free protein synthesis has transformative potential for synthetic biology, yet the prohibitive costs of PURE kits and the labor intensity of in-house preparation have restricted accessibility and scalability. We developed i-POPFLEX (Purified components OPtimized for FLEXible protein expression), a modular cell-free protein synthesis system in which 34 translation factors, individually synthesized in vitro, are assembled using automated liquid handling. This workflow minimizes manual input and supports parallelized production, generating complete, ready-to-use systems within two days. i-POPFLEX achieves up to 5-fold higher protein yields and a 95 % cost reduction (20-fold lower cost) compared with commercial kits. Its flexible architecture also enables selective component inclusion for genetic code reprogramming and site-specific incorporation of non-canonical amino acids. By coupling modular design with automation, i-POPFLEX provides an accessible, customizable, and economically viable platform for next-generation biomanufacturing workflows. Technology readinessi-POPFLEX is a reconstituted cell-free system (CFS) composed of 34 translational components that are individually synthesized in vitro and assembled by automation. This system achieves up to 5-fold higher protein yields with a 95 % cost reduction (20-fold lower; <USD 0.06 {micro}L-1) compared with commercial PURE kits (USD 1.36 {micro}L-1) and reduces preparation time from four days to two. The workflow has been validated across diverse protein and peptide synthesis applications, including genetic code reprogramming and site-specific incorporation of non-canonical amino acids, and integrates seamlessly with benchtop automated liquid-handling platforms. These capabilities place i-POPFLEX at Technology Readiness Level (TRL) 4-5: integrated components validated in a laboratory setting and advancing toward pilot-scale readiness. For full-scale deployment, several key challenges remain. Matching crude lysate costs (USD 0.03 {micro}L-1) will require bulk reagent production, optimized procurement strategies, and specialized equipment for high-throughput component synthesis. Enabling milliliter- and liter-scale production will demand improvements in upstream synthesis, downstream purification, and quality control to ensure consistent performance at industrial throughput. Overcoming these barriers would enable production of thousands to millions of fully assembled i-POPFLEX systems for biofoundry-scale enzyme engineering, metabolic pathway prototyping, and large-scale variant screening, democratizing reconstituted CFS technology, and accelerating adoption in next-generation biomanufacturing pipelines.

synthetic biology↗

RAF isoform selectivity of MEK inhibitors and rational design of a covalent ARAF-MEK inhibitor

Aberrant activation of the RAS/RAF/MEK/ERK pathway is a frequent cause of cancer. Allosteric MEK inhibitors block this pathway by binding RAF-MEK complexes to prevent activation of MEK by RAF. However, how MEK inhibitor potency varies across the three RAF isoforms remains poorly understood. We profiled seven allosteric MEK inhibitors and observed a striking hierarchy of sensitivity: all most potently inhibited CRAF-driven MEK activation while relatively sparing ARAF-driven activation. We identified point mutations in ARAF and CRAF proximate to the MEK inhibitor binding site that markedly altered inhibitor sensitivity. Using a rational design approach, we developed a more potent inhibitor of ARAF-driven MEK signaling, TWG-07-148. Our cryo-EM structure shows how this acrylamide-containing analog of MEK inhibitor trametinib covalently targets Cys514, a residue unique to ARAF. Our studies highlight the importance of the activating RAF isoform as a determinant of MEK inhibitor sensitivity and provide proof-of-concept for development of MEK inhibitors that more effectively block ARAF-driven MEK signaling via covalent targeting of Cys514.

biochemistry↗

M1 Macrophage-Derived Small Extracellular Vesicles as Synergistic Nanotherapeutics: Harnessing Intrinsic Anticancer Activity and Drug Delivery Capacity

Small extracellular vesicles (sEVs) have emerged as next-generation multifunctional nanotherapeutics due to their parental-cell traits and role in intercellular communication. Among them, immune cell-derived sEVs are uniquely positioned to couple innate immunomodulatory activities with therapeutic payload delivery, making them highly attractive for cancer therapy. In particular, M1 macrophage-derived sEVs (M1-sEVs) preserve the tumor-suppressive functions of their parent cells, including tumor microenvironment (TME) reprogramming, immune activation, and inhibition of cancer progression. However, the mechanisms by which these activities are coordinated within the TME, and whether they act independently or synergistically, remain poorly understood. Clarifying these mechanisms is crucial for harnessing their intrinsic bioactivity in combination with their natural capacity as drug delivery nanocarriers to optimize therapeutic efficacy. Here, we demonstrate that M1-sEVs exhibit intrinsic stability and circulation longevity via do not eat me ligands, as well as tumor-homing ability revealed by proteomic profiling, enabling efficient uptake and deep infiltration in breast cancer models. Functionally, M1-sEVs deliver antiproliferative microRNAs that suppress tumor metabolism, growth, and progression by inhibiting self-renewal, adhesion, migration, motility, and invasion. Importantly, by integrating this endogenous bioactivity with exogenous doxorubicin loading, we achieved synergistic efficacy: a 3-fold reduction in IC50 in vitro (0.46 M vs. 1.45 M for free drug) and 70.18% tumor growth inhibition in vivo. These findings highlight M1-sEVs as dual-action nanotherapeutics that combine innate immune-regulatory and tumor-inhibitory functions with efficient drug delivery, advancing their development as powerful platforms for cancer therapy.

bioengineering↗

Nanochirality-programmed Type-I photosensitizer enables deep-tumor photodynamic therapy by reducing extracellular-matrix adhesion

Tumor hypoxia and poor penetration of therapeutics across tumor-microenvironment barriers remain major obstacles to effective cancer therapy, including photodynamic therapy (PDT). Here we introduce a nanochirality-programmed assembly (L-Chi-GAIN) in which nanochirality drives site-selective assembly that activates oxygen-independent Type-I reactive oxygen species (ROS) generation and reduces hyaluronan-mediated matrix adhesion, thereby permitting deep intratumoral therapy. Glycosylation imparts structural chirality to graphene quantum dots (GQDs), directing site-selective assembly of indocyanine green (ICG) that turns on photoinduced electron transfer (PET), producing a 64-fold increase in ROS relative to free ICG. Nanochirality also modulates assembly-extracellular matrix (ECM) interactions. L-GQDs show a less favorable hyaluronan binding free energy ({Delta}Gbind), thus accelerating interstitial transport and resulting in [~]21-fold deeper tumor penetration by L-Chi-GAIN than conventional nanocarriers. Under near-infrared irradiation, L-Chi-GAIN elicits strong oxidative stress and triggers Gasdermin-D (GSDMD)-dependent pyroptosis, leading to significant suppression of tumor growth. This work offers a nanochirality-guided design strategy for PDT in deep tumors by coupling site-selective assembly with stereoselective navigation of the ECM.

bioengineering↗

Nanoscopy of Organelle Handoff Portals Reveals Direct Coupling between ER Remodeling and Microtubule-Based Transport

How biosynthetic organelles leave the endoplasmic reticulum (ER) and engage with microtubule tracks remains a central question. Combining interferometric scattering with fluorescence nanoscopy, we tracked nanometer-scale handoff events in living cells. ER-derived organelles undergo biased diffusion along ER tubules toward nearby microtubules. ER three-way junctions function as nanoscopic hubs where cargo pauses, contacts multiple microtubules, and then launches onto a track for long-range travel. Remarkably, the ER maintains a membrane tether to the departing cargo, extending its tubules and forming new junctions, thereby coupling inter-network transfer with membrane morphogenesis. These observations reveal an integrated mechanism that links organelle biogenesis, directional trafficking, and continual ER- and cellular remodeling, underscoring the ERs active role in steering transport and repurposing its own output within the crowded intracellular environment.

cell biology↗

O-mannosylation and protein maturation check-points represent therapeutic opportunities in BRAF fusion protein oncogenesis

Fusions between protein-coding genes are common oncogenic drivers across cancers, typically pairing a proto-oncogene with partner that does not independently drive cancer. In all therapeutically actionable fusions, the proto-oncogene is the drug target, the contributions to oncogenicity of the fusion partner have largely been ignored. We studied the role of BRAF fusion partners and found that they are necessary for transformation. In the setting of KIAA1549::BRAF, the most common fusion protein across brain tumors, we found that KIAA1549 is necessary for the oncogenicity of KIAA1549::BRAF and engenders a striking and specific dependency on the protein O-mannosyltransferase complex (POMT1/2). Specifically, we show that genetic silencing or pharmacologic inhibition of the protein O-mannosyltransferase complex (POMT1/2) reverses fusion-induced transformation, thereby representing a novel and MAPK independent therapeutic target. Furthermore, POMT1/2 is required to glycosylate and enable maturation of the K::B fusion protein. These findings represent a proof-of-concept for targeting the partners in oncogenic fusions as a potential cancer therapeutic strategy.

cancer biology↗

High-resolution cryo-EM structures of small protein-ligand complexes near the theoretical size limit

Cryo-electron microscopy (cryo-EM) is widely used to determine macromolecular structures at atomic resolution. The theoretical size lower limit of particles for cryo-EM analysis is 38 kDa, limited by factors such as contrast and particle alignment accuracy. To date, no cryo-EM structures have been reported for proteins near this size limit. This study presents cryo-EM structures of two protein-ligand complexes around 40 kDa. The structure of maltose-binding protein (43 kDa) was determined at 2.32 [A] resolution, clearly revealing the bound maltose and water molecules. Additionally, the kinase domain of human PLK1 (37 kDa), slightly below the theoretical limit, was determined at 3.04 [A] resolution, allowing the identification of the bound ligand, onvansertib. These findings demonstrate that cryo-EM can be effectively employed for structure determination and structure-based drug screening of small proteins or domains.

biophysics↗

Automated High-Content, High-Throughput Spatial Analysis Pipeline for Drug Screening in 3D Tumor Spheroid Inverted Colloidal Crystal Arrays

High-content, high-throughput (HCHT) screening platforms are essential for drug discovery, yet conventional 2D assays lack physiological relevance, and current 3D spheroid systems often face challenges to scalability, uniformity, and the analytical efficiency required for statistically robust screening. Here, we present a fully integrated 3D HCHT platform that synergizes tumor spheroid arrays generated from a bioinert inverted colloidal crystal (iCC) hydrogel frame-work with an automated, high-speed image analysis pipeline for rapid and spatially resolved therapeutic profiling. The iCC framework enables spontaneous self-assembly of highly-ordered tumor spheroid array at high spheroid density ([~]79.8 spheroids{middle dot}mm-2) with tight size uniformity (<10% standard deviation), supporting reproducible and high-content imaging ([~]40 spheroids{middle dot}image-1). The automated image-processing algorithm achieves robust region-of-interest segmentation, fluorescence-weighted centroiding, and multi-parametric spatial analysis in <5 seconds per image--markedly faster than conventional well-plate (5 min per 96 throughput) or single-spheroid analysis workflows methods ([~]1 sec per spheroid). Using this platform, we capture dose-dependent diffusion of doxorubicin, tumor penetration profile of small extracellular vesicles, and cell-type-specific infiltration behaviors of monocytes versus macrophages. Comparative viability profiling across chemotherapeutics further reveals distinct spatial toxicity signatures, highlighting the importance of spatial context in drug response assessment. Collectively, this platform enables rapid, reproducible, and spatially informative screening in 3D, offering a powerful tool for drug discovery, tumor modeling, and immunotherapeutic development.

cancer biology↗

Identification of TAP2 protein variants resistant to inhibition by the HSV1 ICP47 protein

Herpes Simplex Virus 1 evades the host immune system by expressing a protein, ICP47, that binds to and inhibits the heterodimeric Transporter Associated with Antigen Processing (TAP). We screened a library of 1786 variants in TAP2, one of the components of the TAP heterodimer, and identified 39 variants that were resistant to inhibition by ICP47. Of these 39 variants, five were individually tested, and three (T257I, S274H, and T244R) were confirmed to be significantly resistant to inhibition by ICP47. This resistance to inhibition did not extend to the Epstein Barr Virus BNLF2a protein, another viral factor known to inhibit antigen presentation by targeting TAP. These three residues localize close to the binding site of ICP47, on the 3D structure of TAP, but only Ser274 is spatially close to the antigenic peptide binding site of TAP. These results functionally resolve the TAP2 residues required for peptide binding from those required for ICP47 binding and identify TAP2 residues whose targeting with small molecule inhibitors could effectively prevent Herpes virus downregulation of antigen processing. AUTHOR SUMMARYT cells detect virus infected cells via viral peptides in complex with the major histocompatibility complex type I (MHC-I) on the cell surface. Herpes Simplex Virus 1 expression of the ICP47 protein allows the virus to evade detection and clearance of infected cells by host T cells. ICP47 binds to the TAP1/TAP2 protein complex and prevents the loading of antigenic peptides onto the MHC-I protein complex and thereby blocks the antigen processing. In this study, we screened for and identified variants of TAP2 with single amino acid substitutions that are no longer inhibited by ICP47. TAP2 proteins with the identified amino acid substitutions functioned normally in antigen processing even in the presence of ICP47. Results from this study create the potential strategy for drugs that target the identified portions of the TAP2 protein and block ICP47 inhibition of antigen processing while retaining normal TAP1/TAP2 function and thus suggest a new antiviral therapeutic approach for herpes virus infections.

immunology↗

Multiplexed functional analysis of TAP2 variants in regulating MHC-I cell surface abundance reveals overexpression of PLK1 downregulates antigen presentation.

The abundance of MHC-I on the cell surface depends on its association with antigenic peptides transported to the endoplasmic reticulum by the Transporter Associated with Antigen Processing (TAP), a peptide channel composed of TAP1 and TAP2. We functionally screened over 1400 TAP2 variants for effects on MHC-I cell surface abundance. Amino-acid substitutions of loss of function (LOF) variants clustered in the NTP-binding domain and along the TAP1-TAP2 binding interface, suggesting that these variants interfered with TAP conformational changes associated with peptide transport. Some LOF variants carried potential phosphomimetic substitutions; one such substitution at Ser251 was embedded in a sequence context consistent with the phosphorylation motif of PLK kinases. Inhibition of PLK kinases increased MHC-I surface expression, while overexpression of PLK1 in cells decreased MHC-I in wild type TAP2, but not in TAP2-S251A-expressing cells. Importantly, site-specific phosphorylation of TAP2 in human tumor samples correlated with alterations of gene expression in the cell cycle and antigen presentation pathways, consistent with the notion that phosphorylation downregulates antigenic peptide transport in human tumors. These data strongly support the hypothesis that in cancer cells, TAP2 phosphorylation by PLK1, and perhaps other kinases, can downregulate the antigen presentation process.

cancer biology↗

spaDesign: A Statistical Framework to Improve the Design of Sequencing-based Spatial Transcriptomics Experiments

MotivationRigorous experimental design is essential for obtaining biologically meaningful findings and high-throughput spatial transcriptomics studies are not an exception. While some efforts have been made to improve the design of these studies, it is still significantly understudied yet how to optimize key experimental factors of these experiments. In the case of sequencing-based spatial transcriptomics studies, determining the minimum sequencing depth is an important experimental factor to decide. ResultsTo address this critical limitation, here we propose spaDesign, a statistical framework to improve the design of sequencing-based spatial transcriptomics experiments. spaDesign is a statistically rigorously designed framework that employs Poisson Gaussian process and Fisher-Gaussian kernel mixture. It can easily simulate a range of spatial transcriptomics data with various sequencing depths, effect sizes, and spatial patterns, which allows rigorous estimation of needed total sequencing depths to detect spatial domains based on spatial transcriptomics experiments. We demonstrated the utility and power of spaDesign using 10X Visium data of the human brain and the chicken heart. AvailabilityThe R package and associated tutorial are freely available at https://github.com/JuanXie19/spaDesign.

bioinformatics↗